The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Risk of cardiovascular events in patients with hypertriglyceridemia: a review of real-world evidence.
Risk of cardiovascular events in patients with hypertriglyceridemia: a review of real-world evidence
A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States.
Cost-effectiveness of icosapent ethyl in REDUCE-IT [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association